{"transactions":[{"id":3924031,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-05-21T18:32:34.000Z","date":"2018-05-18","kind":"sale","acquired":false,"shares":25860,"price":50.03,"value":1293775.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $50.00 to $50.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":107972,"source":{"system":"sec-edgar","filing":"0001209191-18-032073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118032073/doc4.xml","form_type":"4"}},{"id":3930869,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Restricted Stock Units","published_at":"2018-05-16T20:38:50.000Z","date":"2018-05-15","kind":"exercise","acquired":false,"shares":4808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4808},"source":{"system":"sec-edgar","filing":"0001209191-18-030724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118030724/doc4.xml","form_type":"4"}},{"id":3930868,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-05-16T20:38:50.000Z","date":"2018-05-16","kind":"sale","acquired":false,"shares":300,"price":46.3,"value":13890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."}],"balance_after":133832,"source":{"system":"sec-edgar","filing":"0001209191-18-030724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118030724/doc4.xml","form_type":"4"}},{"id":3930867,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-05-16T20:38:50.000Z","date":"2018-05-16","kind":"sale","acquired":false,"shares":4347,"price":46.04,"value":200135.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.25 to $46.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":134132,"source":{"system":"sec-edgar","filing":"0001209191-18-030724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118030724/doc4.xml","form_type":"4"}},{"id":3930866,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-05-16T20:38:50.000Z","date":"2018-05-15","kind":"exercise","acquired":true,"shares":4808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":138479,"source":{"system":"sec-edgar","filing":"0001209191-18-030724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118030724/doc4.xml","form_type":"4"}},{"id":3973183,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-04-03T16:14:23.000Z","date":"2018-03-29","kind":"sale","acquired":false,"shares":22400,"price":40.07,"value":897568.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":133671,"source":{"system":"sec-edgar","filing":"0001209191-18-022904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118022904/doc4.xml","form_type":"4"}},{"id":3980874,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"exercise","acquired":false,"shares":11406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014."}],"balance_after":3125,"derivative":{"exercise_price":11,"expiration_date":"2021-10-14","underlying":"Common Stock","underlying_shares":11406},"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980873,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"exercise","acquired":false,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following December 17, 2015."}],"balance_after":32500,"derivative":{"exercise_price":22.72,"expiration_date":"2022-12-17","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980872,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"exercise","acquired":false,"shares":28848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following January 16, 2015."}],"balance_after":11194,"derivative":{"exercise_price":25.15,"expiration_date":"2022-01-16","underlying":"Common Stock","underlying_shares":28848},"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980871,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"sale","acquired":false,"shares":11103,"price":41.1,"value":456333.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."}],"balance_after":156071,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980870,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"sale","acquired":false,"shares":2800,"price":40.4,"value":113120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":167174,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980869,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"sale","acquired":false,"shares":2170,"price":39.53,"value":85780.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.85 to $39.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":169974,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980868,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"sale","acquired":false,"shares":29980,"price":38.23,"value":1146135.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.80 to $38.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":172144,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980867,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"sale","acquired":false,"shares":31356,"price":37.1,"value":1163307.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.75 to $37.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":202124,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980866,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"sale","acquired":false,"shares":22794,"price":36.43,"value":830385.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.70 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":233480,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980865,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"exercise","acquired":true,"shares":11406,"price":11,"value":125466.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."}],"balance_after":256274,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980864,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"exercise","acquired":true,"shares":32500,"price":22.72,"value":738400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."}],"balance_after":244868,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":3980863,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-03-28T20:10:08.000Z","date":"2018-03-27","kind":"exercise","acquired":true,"shares":28848,"price":25.15,"value":725527.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."}],"balance_after":212368,"source":{"system":"sec-edgar","filing":"0001209191-18-021991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118021991/doc4.xml","form_type":"4"}},{"id":4047719,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-20T20:23:56.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":7211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":4808,"derivative":{"underlying":"Common Stock","underlying_shares":7211},"source":{"system":"sec-edgar","filing":"0001209191-18-011669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118011669/doc4.xml","form_type":"4"}},{"id":4047718,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:23:56.000Z","date":"2018-02-15","kind":"tax_withholding","acquired":false,"shares":3604,"price":47.05,"value":169568.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":183520,"source":{"system":"sec-edgar","filing":"0001209191-18-011669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118011669/doc4.xml","form_type":"4"}},{"id":4047717,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-02-20T20:23:56.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":7211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":187124,"source":{"system":"sec-edgar","filing":"0001209191-18-011669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118011669/doc4.xml","form_type":"4"}},{"id":4066220,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-02-12T20:56:32.000Z","date":"2018-02-09","kind":"tax_withholding","acquired":false,"shares":3704,"price":41.7,"value":154456.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":179913,"source":{"system":"sec-edgar","filing":"0001209191-18-009409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118009409/doc4.xml","form_type":"4"}},{"id":4070457,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-08T17:43:52.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018."}],"balance_after":50000,"derivative":{"exercise_price":35.8,"expiration_date":"2025-02-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-18-008509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118008509/doc4.xml","form_type":"4"}},{"id":4070456,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-02-08T17:43:52.000Z","date":"2018-02-06","kind":"tax_withholding","acquired":false,"shares":4437,"price":35.8,"value":158844.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":183617,"source":{"system":"sec-edgar","filing":"0001209191-18-008509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118008509/doc4.xml","form_type":"4"}},{"id":4070455,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2018-02-08T17:43:52.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2 shares issued on October 30, 2017 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":188054,"source":{"system":"sec-edgar","filing":"0001209191-18-008509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919118008509/doc4.xml","form_type":"4"}},{"id":4158232,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Restricted Stock Unites","published_at":"2017-11-17T18:26:08.000Z","date":"2017-11-15","kind":"exercise","acquired":false,"shares":7212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":12019,"derivative":{"underlying":"Common Stock","underlying_shares":7212},"source":{"system":"sec-edgar","filing":"0001209191-17-061606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117061606/doc4.xml","form_type":"4"}},{"id":4158231,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-11-17T18:26:08.000Z","date":"2017-11-16","kind":"sale","acquired":false,"shares":3290,"price":14.2,"value":46718.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligation from settlement of vested restricted stock units."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016."}],"balance_after":163052,"source":{"system":"sec-edgar","filing":"0001209191-17-061606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117061606/doc4.xml","form_type":"4"}},{"id":4158230,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-11-17T18:26:08.000Z","date":"2017-11-15","kind":"exercise","acquired":true,"shares":7212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":166342,"source":{"system":"sec-edgar","filing":"0001209191-17-061606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117061606/doc4.xml","form_type":"4"}},{"id":4230775,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Restricted Stock Unites","published_at":"2017-08-17T17:34:54.000Z","date":"2017-08-15","kind":"exercise","acquired":false,"shares":7211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":19231,"derivative":{"underlying":"Common Stock","underlying_shares":7211},"source":{"system":"sec-edgar","filing":"0001209191-17-049447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117049447/doc4.xml","form_type":"4"}},{"id":4230774,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-08-17T17:34:54.000Z","date":"2017-08-16","kind":"sale","acquired":false,"shares":3021,"price":14.33,"value":43290.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover tax obligation from settlement of vested restricted stock units."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016."}],"balance_after":159130,"source":{"system":"sec-edgar","filing":"0001209191-17-049447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117049447/doc4.xml","form_type":"4"}},{"id":4230773,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-08-17T17:34:54.000Z","date":"2017-08-15","kind":"exercise","acquired":true,"shares":7211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,940 shares issued on May 31, 2017 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":162151,"source":{"system":"sec-edgar","filing":"0001209191-17-049447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117049447/doc4.xml","form_type":"4"}},{"id":4315835,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Restricted Stock Unites","published_at":"2017-05-17T16:57:39.000Z","date":"2017-05-15","kind":"exercise","acquired":false,"shares":7212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":26442,"derivative":{"underlying":"Common Stock","underlying_shares":7212},"source":{"system":"sec-edgar","filing":"0001209191-17-033189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117033189/doc4.xml","form_type":"4"}},{"id":4315834,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-05-17T16:57:39.000Z","date":"2017-05-16","kind":"sale","acquired":false,"shares":3873,"price":15.25,"value":59063.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligation from settlement of vested restricted stock units."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016."}],"balance_after":153000,"source":{"system":"sec-edgar","filing":"0001209191-17-033189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117033189/doc4.xml","form_type":"4"}},{"id":4315833,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-05-17T16:57:39.000Z","date":"2017-05-15","kind":"exercise","acquired":true,"shares":7212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":156873,"source":{"system":"sec-edgar","filing":"0001209191-17-033189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117033189/doc4.xml","form_type":"4"}},{"id":4442725,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Restricted Stock Unites","published_at":"2017-02-16T20:09:34.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":7211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":33654,"derivative":{"underlying":"Common Stock","underlying_shares":7211},"source":{"system":"sec-edgar","filing":"0001209191-17-011765","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117011765/doc4.xml","form_type":"4"}},{"id":4442724,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-02-16T20:09:34.000Z","date":"2017-02-16","kind":"sale","acquired":false,"shares":3059,"price":15.96,"value":48821.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover tax obligation from settlement of vested restricted stock units."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016."}],"balance_after":149661,"source":{"system":"sec-edgar","filing":"0001209191-17-011765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117011765/doc4.xml","form_type":"4"}},{"id":4442723,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-02-16T20:09:34.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":7211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 822 shares issued on November 30, 2016 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":152720,"source":{"system":"sec-edgar","filing":"0001209191-17-011765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117011765/doc4.xml","form_type":"4"}},{"id":4461567,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2017-02-08T17:34:43.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":49500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."}],"balance_after":144687,"source":{"system":"sec-edgar","filing":"0001209191-17-008810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919117008810/doc4.xml","form_type":"4"}},{"id":4550519,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R & QA Officer"}}],"security":"Restricted Stock Unites","published_at":"2016-11-17T16:28:38.000Z","date":"2016-11-15","kind":"exercise","acquired":false,"shares":7212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The earlier of (i) March 27, 2021 or (ii) the recepient's termination date."}],"balance_after":40865,"derivative":{"underlying":"Common Stock","underlying_shares":7212},"source":{"system":"sec-edgar","filing":"0001209191-16-150862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919116150862/doc4.xml","form_type":"4"}},{"id":4550518,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2016-11-17T16:28:38.000Z","date":"2016-11-16","kind":"sale","acquired":false,"shares":2995,"price":19.53,"value":58492.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligation from settlement of vested restricted stock units."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016."}],"balance_after":95187,"source":{"system":"sec-edgar","filing":"0001209191-16-150862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919116150862/doc4.xml","form_type":"4"}},{"id":4550517,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":166479,"kind":"person","name":"Clark Mitchall G.","position":1,"cik":"0001612094","reported_name":"Clark Mitchall G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R & QA Officer"}}],"security":"Common Stock","published_at":"2016-11-17T16:28:38.000Z","date":"2016-11-15","kind":"exercise","acquired":true,"shares":7212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":98182,"source":{"system":"sec-edgar","filing":"0001209191-16-150862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612094/000120919116150862/doc4.xml","form_type":"4"}}]}